



PubMed	Nucleotide	Protein	Genome	Structure	PopSet	Taxonomy	OMIM
Search PubMed	[v] for					Go	Clear
Limits		Preview/Index		History		Clipboard	Delta
Display	Abstract	[v] Sort	[v] Save	Text	Clip Add	Order	

Entrez PubMed

☐ 1: J Infect Dis 1995 May;171(5):1107-14 [Related Articles, Books, LinkOut](#)

**A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children.**

PubMed Services

**Karron RA, Wright PF, Hall SL, Makhene M, Thompson J, Burns BA, Tollefson S, Steinhoff MC, Wilson MH, Harris DO, et al.**

Department of International Health, School of Hygiene and Public Health, Johns Hopkins University, Baltimore, Maryland, USA.

Related Resources

The safety, infectivity, immunogenicity, transmissibility, and phenotypic stability of an intranasal bovine parainfluenza virus type 3 (BPIV-3) candidate vaccine was evaluated in a randomized, double-blind, placebo-controlled trial. Of human parainfluenza virus type 3 (HPIV-3)-seronegative children, 92% were infected, and 92% developed a serum hemagglutination-inhibiting (HAI) antibody response to BPIV-3 and 61% to HPIV-3. Geometric mean HAI titers were 1:40 to BPIV-3 and 1:16 to HPIV-3. In studies to evaluate vaccine transmissibility, none of 14 placebo recipients in close contact with 14 vaccinees shed BPIV-3. BPIV-3 isolates from seronegative vaccinees retained the attenuation phenotype when tested in rhesus monkeys. Although it is difficult to evaluate the safety and immunogenicity of such a vaccine in an open population of children who frequently become infected with HPIV-3, it appears that the live BPIV-3 vaccine is attenuated, infectious, immunogenic, poorly transmissible, and phenotypically stable and warrants further evaluation as a candidate vaccine in infants and children.

**Publication Types:**

- Clinical Trial
- Clinical Trial, Phase I
- Multicenter Study
- Randomized Controlled Trial

PMID: 7751684 [PubMed - indexed for MEDLINE]